Intrinsic factor antibody · autoimmune gastritis

Intrinsic Factor Antibody: Screening for Autoimmune Gastritis

An intrinsic factor antibody is highly specific for autoimmune gastritis but insensitive: 100% specificity and 38% sensitivity in a recent assay comparison, so a negative result settles little. Ordered together with anti-parietal cell antibody, the pair reached 90% sensitivity and 95.7% specificity.

Autoimmune gastritis is found when someone looks for it. The serology fails in predictable directions, and the patients at risk are easy to flag before their nerves and memory pay for the delay.

An intrinsic factor antibody is one of the few results in a B12 workup that can close a diagnosis on its own, and one of the least informative when it comes back negative. Most practices order it late, order it alone, and read a negative as reassurance. The video The Normal B12 That Wasn’t, from The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, walks through a patient who lost four years to exactly that sequence. For a primary care, endocrine, geriatric or pain practice the practical questions are narrower: who to screen for autoimmune gastritis, how to read the serology, and what a finding changes downstream in nerve, balance and cognitive function.

Intrinsic factor antibody vs. parietal cell antibody: how does each test fail?

Anti-intrinsic factor antibody carried a specificity of 100% and a sensitivity of 38% in a recent assay comparison. A United States society review puts its sensitivity under 30% in many studies and notes that it is more often positive later in the disease course. The test that proves the diagnosis turns positive after much of the damage is done. More than half of people with symptomatic B12 deficiency test negative for both antibodies.

Anti-parietal cell antibody has the opposite profile. It is present in 85% to 90% of patients with autoimmune gastritis, but about 10% of the general population carries it, it turns positive in H. pylori gastritis and autoimmune thyroid disease, and it becomes less reliable in patients aged 50 and over, which is where the disease concentrates. Combined, the pair performed at 90% sensitivity with 95.7% specificity.

Two workflow consequences follow. Order both, not one. And do not trend the parietal cell titer: in 282 patients followed for 18 years, neither its presence nor its value predicted histologic progression.

Who to screen: the profile the stereotype hides

The teaching image of an older Northern European woman misses much of the population. In a Miami biopsy series, 60 of 79 cases, 76.0%, were Hispanic, and the median age at first presentation was 51 years in Hispanic patients against 59 in White patients. Symptoms do not select either; in pooled data, gastric precursor lesions were no more common in symptomatic than in asymptomatic people. The median diagnostic delay in the autoimmune gastritis literature is 14 months. A reasonable screening trigger list, built from the same evidence:

• Autoimmune thyroid disease. About 40% of these patients have atrophic body gastritis, and 16% carry pernicious anemia.
• Type 1 diabetes. Risk of autoimmune gastritis runs roughly three to five times the general population.
• Unexplained iron deficiency. In corpus-predominant atrophy it appears in as many as half of patients and often precedes the B12 fall.
• Long-term metformin or acid suppression. In a randomized placebo-controlled trial over 4.3 years, metformin lowered serum B12 by 19%, number needed to harm 13.8. A supply of proton pump inhibitor lasting at least two years was associated with deficiency at an odds ratio of 1.65.
• Gastric bypass. Pooled randomized trials put its B12 deficiency risk at 1.86 times that of sleeve gastrectomy.

Case-finding pays off in the data. In the Italian network cohort, 15.3% of antibody-positive patients were identified by active search rather than symptoms, against 2.6% of antibody-negative patients. The social driver sits underneath the pharmacology: a food supply that manufactures insulin resistance and reflux, treated with drugs that draw the vitamin down. That background metaflammation is the terrain the first brain is failing in.

What does a positive or equivocal intrinsic factor antibody change?

I spent years repeating that gastric acid output simply declines with age. It does not; adjusted for gastritis and H. pylori, age had no independent effect. A patient with low acid and low B12 has a lesion, and the workup should treat it as one.

Confirm functional status first. Holotranscobalamin below 25 pmol/L indicates deficiency, and 25 to 70 is indeterminate. Methylmalonic acid above 280 nmol/L suggests suboptimal status in younger patients with normal renal function, and above 750 nmol/L is accepted as definite, read in light of renal impairment, dehydration and small-bowel bacterial overgrowth. Gastrin drawn on a proton pump inhibitor is raised three to five times and reports on the drug. Pepsinogen testing is not available for routine clinical use in the United States.

Then look at the lining. European guidance asks for at least two biopsies from the antrum or incisura and two from the corpus, in separately labeled vials. Only 9% of patients with pernicious anemia were offered gastroscopy at diagnosis in one recent study. The yield is not academic: in 1,598 Italian patients with autoimmune gastritis, presenting with low B12 or low iron predicted neuroendocrine tumors, hazard ratio 16.44, while progression from atrophic gastritis to adenocarcinoma runs about 0.1% to 0.3% per year. On route of replacement, the 2024 English guideline recommends lifelong intramuscular therapy where autoimmune gastritis is the cause; the largest oral trial enrolled only 10.8% intrinsic factor antibody-positive patients.

Pairing the serology with nerve, balance and cognition

Serology locates the cause. It does not tell you what the deficiency has already cost. Measura [Cardiometabolic and Autonomic Health Analysis] measures that downstream picture and returns it to the ordering physician; it does not diagnose gastritis and it does not treat.

• Sudomotor testing quantifies sudomotor output as a window on distal small-fiber integrity.
• Vestibular and balance testing quantifies postural stability in a patient whose sensory neuropathy is changing gait.
• Cognitive assessment sets a baseline before replacement, so recovery or its absence is documented.
• Laboratory panels capture the insulin resistance behind the metformin prescription.

That pairing belongs inside existing fall-risk and cognitive screening, as outlined in cognitive assessment and fall prevention. The related case for functional B12 markers in metformin-treated patients is in metformin and B12 screening beyond the serum level, and the cognitive overlap in B vitamins in mild cognitive impairment.

Documentation, standing orders and workflow

This screen only works if it runs without a physician remembering it. A standing order can attach both gastric antibodies and a functional B12 marker to the trigger list above, flag unexplained low ferritin for the same bundle, and route positives to gastroenterology with the biopsy protocol spelled out. The annual wellness visit already carries cognitive and fall-risk elements that the nerve and balance measurements document, and the same findings support MIPS quality documentation. For operational detail, see making screening reproducible with standing orders. The full evidence file is in the companion deep dive for The Angry Gut, and the patient-facing explanation is atrophic gastritis and B12 absorption.

Frequently asked questions

References

• Osmola, M., Hémont, C., Romańczyk, M., Druet, A., Chapelle, N., Matysiak-Budnik, T., Lenti, M. V., & Martin, J. C. (2025). A comparative study of different assays for autoantibodies detection in patients with autoimmune gastritis. Journal of Translational Autoimmunity, 10, 100294. https://doi.org/10.1016/j.jtauto.2025.100294
• Rustgi, S. D., Bijlani, P., & Shah, S. C. (2021). Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management. Therapeutic Advances in Gastroenterology, 14, 17562848211038771. https://doi.org/10.1177/17562848211038771
• Shah, S. C., Piazuelo, M. B., Kuipers, E. J., & Li, D. (2021). AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology, 161(4), 1325–1332.e7. https://doi.org/10.1053/j.gastro.2021.06.078
• Thain, A., Hart, K., & Ahmadi, K. R. (2025). Addressing the gaps in the vitamin B12 deficiency 2024 NICE guidelines: Highlighting the need for better recognition, diagnosis, and management of pernicious anaemia. European Journal of Clinical Nutrition, 79(7), 607-610. https://doi.org/10.1038/s41430-025-01583-4
• Poveda, J. C., Park, J. Y., Garcia-Buitrago, M. T., Singhi, A., Alruwaii, Z., Kumar, S., McDonald, O. G., & Montgomery, E. A. (2024). Autoimmune Metaplastic Atrophic Gastritis (AMAG): Regional Demographics and Their Effect on Prevalence. International Journal of Surgical Pathology, 33(3), 565–570. https://doi.org/10.1177/10668969241271311
• Harrington, D. J., Stevenson, E., & Sobczyńska-Malefora, A. (2024). The application and interpretation of laboratory biomarkers for the evaluation of vitamin B12 status. Annals of Clinical Biochemistry, 62(1), 22–33. https://doi.org/10.1177/00045632241292432
• Lenti, M. V., Miceli, E., Lahner, E., Natalello, G., Massironi, S., Schiepatti, A., Zingone, F., Sciola, V., Rossi, R. E., Cannizzaro, R., De Giorgi, E. M., Gregorio, V., Fazzino, E., Gentile, A., Petrucci, C., Dilaghi, E., Pivetta, G., Vanoli, A., Luinetti, O., … Di Sabatino, A. (2024). Distinguishing Features of Autoimmune Gastritis Depending on Previous Helicobacter pylori Infection or Positivity to Anti-Parietal Cell Antibodies: Results From the Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO). The American Journal of Gastroenterology, 119(12), 2408–2417. https://doi.org/10.14309/ajg.0000000000002948
• de Jager, J., Kooy, A., Lehert, P., Wulffelé, M. G., van der Kolk, J., Bets, D., Verburg, J., Donker, A. J. M., & Stehouwer, C. D. A. (2010). Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: Randomised placebo controlled trial. BMJ, 340, c2181. https://doi.org/10.1136/bmj.c2181
• Dinis-Ribeiro, M., Libânio, D., Uchima, H., Spaander, M. C. W., Bornschein, J., Matysiak-Budnik, T., Tziatzios, G., Santos-Antunes, J., Areia, M., Chapelle, N., Esposito, G., Fernandez-Esparrach, G., Kunovsky, L., Garrido, M., Tacheci, I., Link, A., Marcos, P., Marcos-Pinto, R., Moreira, L., … Kuipers, E. J. (2025). Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025. Endoscopy, 57(5), 504–554. https://doi.org/10.1055/a-2529-5025
• National Institute for Health and Care Excellence (NICE) (2024). Vitamin B12 deficiency in over 16s: diagnosis and management (NICE guideline NG239).

Related reading

• MASLD in Primary Care: Screening When Liver Enzymes Look Normal
• Orthostatic Intolerance in Hypermobility: A Primary Care Screen
• Sudomotor Testing

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.